|
|
|
Cough, Cold and Allergy (Hay Fever) Remedies in Dominican Republic
5/9/2012 | published by: Euromonitor International
Generics’ development through the national government public health programme PROMESE/CAL (Programa de Medicamentos Esenciales y Centro de Apoyo Logístico) during 2011 continued to play an important role in the category. This was because lower-income consumers
|
more...
|
$900.00
|
|
Cough, Cold and Allergy (Hay Fever) Remedies in Guatemala
5/10/2012 | published by: Euromonitor International
In 2011 cough, cold and allergy (hay fever) remedies reached GTQ103 million in current value sales after experiencing growth of 6%. The category is one of the largest in the total consumer health market in
|
more...
|
$900.00
|
|
Cough, Cold and Allergy (Hay Fever) Remedies in Latvia
5/8/2012 | published by: Euromonitor International
Cough, cold and allergy (hay fever) remedies had value growth in 2011. However, the number of influenza cases did not change significantly compared to 2010. Fluctuating temperature in summer resulted in higher sales performance of
|
more...
|
$900.00
|
|
Cough, Cold and Allergy (Hay Fever) Remedies in Ukraine
5/10/2012 | published by: Euromonitor International
In Ukraine, self-medication for coughs, colds and allergies is widespread, with consumer knowledge about such medicines boosted by regular TV advertising. While visiting doctors for such ailments is generally avoided due largely to the poor
|
more...
|
$900.00
|
|
Cough, Cold and Allergy (Hay Fever) Remedies in Hong Kong, China
4/16/2012 | published by: Euromonitor International
At the beginning and end of 2011 Hong Kong had unusually cold weather which helped drive sales for cold and cough medication. Heavy air pollution continued to create a number of allergy-related symptoms in consumers,
|
more...
|
$900.00
|
|
Triple Analysis: Lung Cancer, Angiogenesis and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in Lung Cancer and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized
|
more...
|
$5,175.00
|
|
Triple Analysis: Lung Cancer, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lung Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Each of these three individual parts is
|
more...
|
$5,175.00
|
|
Triple Analysis: Lung Cancer, Protein Kinase Inhibitors and Peptides
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lung Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Peptides). Each of these three individual parts is
|
more...
|
$5,175.00
|
|
Bronchopulmonary Dysplasia Global Clinical Trials Review, H1, 2012
4/25/2012 | published by: GlobalData
Bronchopulmonary Dysplasia Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Bronchopulmonary Dysplasia Global Clinical Trials Review, H1, 2012 provides data on the Bronchopulmonary Dysplasia clinical trial scenario. This report provides elemental information and data
|
more...
|
$1,000.00
|
|
Lung Injury Global Clinical Trials Review, H1, 2012
4/25/2012 | published by: GlobalData
Lung Injury Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Lung Injury Global Clinical Trials Review, H1, 2012 provides data on the Lung Injury clinical trial scenario. This report provides elemental information and data
|
more...
|
$1,000.00
|
